Metvix Daylight PDT in Actinic Keratosis
Completed
- Conditions
- Actinic Keratosis
- Registration Number
- NCT02674048
- Lead Sponsor
- Galderma R&D
- Brief Summary
Prospective non-interventional study conducted in Australia, Brazil, Mexico and Europe to evaluate clinical practice with Metvix Daylight PDT in the treatment of mild to moderate actinic keratosis of the face/scalp and to assess physician and patient satisfaction.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 406
Inclusion Criteria
- Patients to whom Metvix® Daylight-PDT has already been prescribed by their physician, according to the local label;
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of physician satisfaction assessed on a 4-point scale from very satisfied to not satisfied with the question "Overall are you satisfied with Metvix DL-PDT?" 3 months Percentage of patient satisfisfaction assessed on a 4-point scale from very satisfied to not satisfied with the question "Overall, how satisfied are you with this treatment?". 3 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (7)
Italy
🇮🇹L'Aquila, Italy
France
🇫🇷Pontoise, France
Alkmaar
🇳🇱Alkmaar, Netherlands
Bern
🇨🇭Bern, Switzerland
Manchester
🇬🇧Manchester, United Kingdom
See Jo-Ann
🇦🇺Sydney, New South Wales, Australia
Madrid
🇪🇸Madrid, Spain